Using similar combinations of rat strains, three sera were raised against the full MHC, the A sub-region, or the B sub-region of H-1[a]. Radio-immunoassay substantiated the expected antigenic targets of these sera. Each of the three sera was able to passively enhance a single haplotype H-1[a] MHC kidney in an H-1[c] recipient leading to long-term survival. Previous researchers have hypothesized that since anti-Ia sera were as effective as anti-MHC sera in producing enhancement, anti-K/D sera played no role. Our data show that the full MHC antigenic difference may be enhanced by 'partial cover' with anti-A or anti-B sera.

Studies on an in vitro assay to predict cross-reactivity of alloantisera for kidney graft enhancement in rats

Judith L.McKENZIE, J.W.Fabre and Peter J.Morris

Nuffield Department of Surgery, University of Oxford, Radcliffe Infirmary, Oxford.

One of the important problems to be encountered when transferring passive enhancement studies from inbred experimental animals to outbred populations such as the human is the difficulty of choosing the appropriate dose and specificity of sera for particular donor-host combinations. In this study we have examined a quantitative binding assay using immunoadsorbent purified, ^{125}I labelled rabbit anti rat immunoglobulin as a possible in vitro assay to predict the enhancing capacity of sera. In an attempt to duplicate in rats the situation in outbred animals, third party and other sera, as well as donor specific sera, were titrated in vivo for their relative enhancing capacities. In the (DA x Lewis) F1 to DA model, it was found that DA anti WAG serum gave excellent enhancement, but a 10-fold higher dose was needed when compared to the specific DA anti Lewis serum. DA anti PVG, PVG anti WAG and WAG anti PVG sera were not effective at 200 times the minimum effective dose of the DA anti Lewis serum. In the (DA x Lewis) F1 to Lewis model, Lewis anti PVG and Lewis anti WAG sera had a slight enhancing effect at 20 times the minimum effective dose of the Lewis anti DA serum. This pattern of crossreactivity was not predicted on the basis of lymphocytotoxicity of the sera against the kidney donor's peripheral blood lymphocytes. The binding assay against donor spleen lymphocytes gave better predictions as to which sera would have an enhancing effect, but dose requirements could not be predicted.

Failure of immunological memory in rats with enhanced kidney allografts

M POOLE, J.R.Batchelor, A.Maynard and H.Burgos

McIndoe Research Unit, Queen Victoria Hospital, East Grinstead, Sussex.

In immunological enhancement of rat kidney allografts many recipients develop a response against the graft during the second week; subsequently this subsides and the graft recovers. If the recipient is later challenged with kidney donor MHC antigens, it does not produce a normal secondary immune response. We suspect this is an example of loss of immunological memory and have questioned whether the presence of antigen is necessary to maintain the loss. We therefore transplanted spleens from these rats into syngeneic recipients, and then challenged with MHC antigen in a form which only provokes secondary responses. As controls, spleens were transplanted from previously immunized rats in which responses had subsided to background levels. The results showed rats receiving spleens from donors with enhanced kidneys produced little or no antibody after challenge. In contrast, control rats produced sustained secondary antibody responses. Approximately 2 months later, a similar re-challenge produced the same results. This experiment demonstrates that the loss of immunological memory by rats with enhanced kidney grafts does not require continued presence of antigen for its maintenance, and suggests that clonal inactivation or elimination is its basis rather than suppressor cells or auto-anti-idiotype antibody formation.

The Wembley Conference Centre Organisers have asked that participants should carry the programme of the meeting as a means of identification.

Further information about the Wembley Meeting may be obtained from Professor A.J.S.Davies or his secretary at the Chester Beatty Research Institute, Fulham Road, London SW3 6JB or telephone (01) 352-8133.

BRITISH SOCIETY FOR IMMUNOLOGY

BRITISH TRANSPLANTATION SOCIETY

JOINT MEETING

WEMBLEY CONFERENCE CENTRE

Thursday, 19th October, 1978

Avon Lecture Theatre — Chairman: Prof. P.J.Morris

10.00 a.m. Dr Hans WIGZELL (University of Uppsala, Sweden)
Generation and regulation of T cell specificity.

11.00 a.m. Coffee

11.30 a.m. Prof. J.Richard BATCHELOR (East Grinstead)
Present thoughts on the mechanisms of immunological enhancement.

12.30 p.m. Lunch

FACILITATION OF HOMOGRAFT ACCEPTANCE

Avon Two Lecture Theatre — Chairman: Prof. L. Brent

2.00 SHAND, F.L. (Beckenham) *
Selective elimination of alloreactive T cells by cyclophosphamide pretreatment in vitro.

2.15 WHITE, D.J.G., R.Y.Calne, K.Rolles and A.Plumb (Cambridge)
Mechanism of action of Cyclosporin A.

2.30 PIERPAOLI, W. and G.J.M.Maestroni (Zürich)
Successful engraftment of allogeneic bone marrow in mice.

2.45 MILTON, J.D. (Liverpool) *
Immunosuppressive activity of anti D end alloantibody.

3.00 GARVEY, J.F.W., P.R.Millard and P.J.Morris (Oxford) *
Failure of enhancing serum to prolong survival of foetal rat pancreas allografts.

3.15 GALLICO, G.G. and G.W.Butcher (Oxford and Cambridge)
Rat kidney transplantation: rejection and enhancement through sub-regions of the major histocompatibility complex.

3.30 Tea

Chairman: Dr J.A.Sachs

4.00 McKENZIE, J.L., J.W.Fabre and P.J.Morris (Oxford)
Studies on an in vitro assay to predict cross-reactivity of alloantisera for kidney graft enhancement in rats.

4.15 POOLE, M., J.R.Batchelor, A.Maynard and H.Burgos (East Grinstead)
Failure of immunological memory in rats with enhanced kidney allografts.

4.30 JEANNET, M., F.Harder and A.Montandon (Geneva) *
Blood transfusions, HLA and DR antibodies and kidney transplant survival: a prospective study.

4.45 EVANS, P.R., D.S.Smith, J.L.Smith, C.Spencer, M.Slapak and H.A.Lee (Southampton and Portsmouth) *
An analysis of serial pre and post transplant sera for antibody activity against neoplastic and normal B cells.

Abstracts for papers marked * appear on pages 11-13 of the full meeting programme.

ABSTRACTS (not for publication)

Mechanism of action of Cyclosporin A

D.J.G.WHITE, R.Y.Calne, K.Rolles and A.Plumb

Dept. of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge.

We have demonstrated Cyclosporin A (Sandoz Ltd) to be a potent suppressor of graft rejection in rats, rabbits, pigs, dogs, monkeys and man. It has been demonstrated in vitro that this agent inhibits T cell proliferation. We now report on the in vivo effect of this agent on T cell responsiveness.

Peripheral blood lymphocytes taken at weekly intervals from pigs with MHC mismatched orthotopic cardiac allografts being immmnosuppressed with 25mg/kg/day of Cyclosporin A showed a marked specific depression in mixed lymphocyte reactions when stimulated with donor cells. These recipient lymphocytes gave normal or near normal responses when stimulated by third party cells. Pre-transplant cells and mixtures of pre and non-responsive post-transplant recipient cells gave normal or elevated responses when stimulated by donor cells, indicating that non-responsiveness in the post-transplant samples was not due to the presence of suppressor cells or donor specific cytotoxic cells. MHC mismatched porcine cardiac allografts receiving no treatment or receiving azathioprine and steroids have a median survival of only 6 days whereas of eight Cyclosporin A treated heart graft recipients six are still living at between 52 and 207 days (median 127).

Cyclosporin A has been tested in limited clinical trials in patients with cadaveric kidney transplants. We will present the results of our studies on the T cell function of these patients. The ability of Cyclosporin A to remove specifically that clone of lymphocytes from the blood which were reactive towards the graft will be discussed in relation to donor specific immunosuppression.

Successful engraftment of allogeneic bone marrow in mice

W.PIERPAOLI and G.J.M.Maestroni

Cell Biology Division, Institute of Anatomy, University of Zürich, Switzerland.

The use of a combination of three drugs (5-hydroxytryptophan, haloperidol and phentolamine) has allowed to achieve a remarkable control of immunological reactions. The application of this system to allogeneic (homologous) bone marrow transplantation (BMT) in lethally irradiated mice (total body irradiation, TBI) seems now to constitute an efficient means for controlling the secondary disease (SD) ensuing in mice transplanted with foreign marrow after TBI, and for achieving a permanent chimerism. In addition, a new pre-conditioning regimen (preceeding TBI) has been developed which facilitates greatly the engraftment of foreign marrow. The final procedure we apply now is based on a) administration of the combination of drugs as a saline suspension sc in recipient mice; b) ip or iv inoculation of allogeneic bone marrow (over $20x10^6$ cells/mouse) one-two hours after the drugs; c) TBI, 800rad (Balb/c, C3H, C57BL/6) or 900rad (hybrid recipients) four-five hours after inoculation of bone marrow and finally d) a second inoculation of allogeneic bone marrow from the same donor strain, iv, immediately after TBI (over $20x10^6$ cells/mouse). This combination of drugs and allogeneic marrow in the pre-conditioning stage (before TBI) and a proper timing of inoculation of the different components allows the elimination of early or late mortality (high survival rate), avoidance of SD and induction of a permanent chimerism, as shown by different techniques. This method is now being applied to BMT in primates.

Rat kidney transplantation: rejection and enhancement through sub-regions of the major histocompatibility complex

G.Gregory GALLICO and Geoffrey W.Butcher

MRC Cellular Immunology Unit, Dunn School of Pathology, Oxford University and ARC Immunology Unit, Institute of Animal Physiology, Cambridge University.

The antigenic target for kidney rejection has not been established, and the antigenic target of enhancement is controversial. The genetics of the mouse major histocompatibility complex (MHC) are sufficiently well known to establish these points, but mice reject kidney allografts poorly. Rats reject kidneys well, but strains did not exist to enable precise genetic analysis.

A recombinant rat strain between the MHC of HO ($H\text{-}1^c$) and DA ($H\text{-}1^a$) was developed and bred to congenicity with the HO background. Analysis of this recombinant strain has led to the hypothesis that the rat MHC consists of an A sub-region analogous to the mouse K and D regions and a B sub-region analogous to the mouse Ir region. Also, a HO·B4 rat strain was developed with a DA ($H\text{-}1^a$) MHC congenic with a HO background.

In addition, we developed a microtiter radio-immunoassay for allospecific rat serum and through binding assays to B or T cells (separated by rosette depletion techniques or on the Fluorescence Activated Cell Sorter) or to RBC, we showed that the recombinant rat strain MHC, designated IR, encoded the K/D like antigens of $H\text{-}1^a$ and the Ia-like antigens of $H\text{-}1^c$.

Left orthotopic kidney transplants were performed between appropriate combinations of HO, IR, and HO·B4 rats. We conclude that whereas a kidney presenting a single haplotype MHC antigenic difference is readily rejected, kidneys presenting A or B sub-region differences alone are accepted. Skin grafts across each of the three antigenic differences were rejected. Renal rejection may require a combined A + B modified target antigen expression by the kidney as has been shown for cell mediated lympholysis. These results are analogous to the tissue typing correlation in human and Rhesus monkey kidney transplants where in unrelated host-donor combinations an LD match may be more important than SD.

Using similar combinations of rat strains, three sera were raised against the full MHC, the A sub-region, or the B sub-region of H-1^a. Radio-immunoassay substantiated the expected antigenic targets of these sera. Each of the three sera was able to passively enhance a single haplotype H-1^a MHC kidney in an H-1^c recipient leading to long-term survival. Previous researchers have hypothesized that since anti-Ia sera were as effective as anti-MHC sera in producing enhancement, anti-K/D sera played no role. Our data show that the full MHC antigenic difference may be enhanced by 'partial cover' with anti-A or anti-B sera.

Studies on an in vitro assay to predict cross-reactivity of alloantisera for kidney graft enhancement in rats

Judith L.McKENZIE, J.W.Fabre and Peter J.Morris

Nuffield Department of Surgery, University of Oxford, Radcliffe Infirmary, Oxford.

One of the important problems to be encountered when transferring passive enhancement studies from inbred experimental animals to outbred populations such as the human is the difficulty of choosing the appropriate dose and specificity of sera for particular donor-host combinations. In this study we have examined a quantitstive binding assay using immunoadsorbent purified, ^{125}I labelled rabbit anti rat immunoglobulin as a possible in vitro assay to predict the enhancing capacity of sera. In an attempt to duplicate in rats the situation in outbred animals, third party and other sera, as well as donor specific sera, were titrated in vivo for their relative enhancing capacities. In the (DA x Lewis) F1 to DA model, it was found that DA anti WAG serum gave excellent enhancement, but a 10-fold higher dose was needed when compared to the specific DA anti Lewis serum. DA anti PVG, PVG anti WAG and WAG anti PVG sera were not effective at 200 times the minimum effective dose of the DA anti Lewis serum. In the (DA x Lewis) F1 to Lewis model, Lewis anti PVG and Lewis anti WAG sera had a slight enhancing effect at 20 times the minimum effective dose of the Lewis anti DA serum. This pattern of crossreactivity was not predicted on the basis of lymphocytotoxicity of the sera against the kidney donor's peripheral blood lymphocytes. The binding assay against donor spleen lymphocytes gave better predictions as to which sera would have an enhancing effect, but dose requirements could not be predicted.

Failure of immunological memory in rats with enhanced kidney allografts

M POOLE, J.R.Batchelor, A.Maynard and H.Burgos

McIndoe Research Unit, Queen Victoria Hospital, East Grinstead, Sussex.

In immunological enhancement of rat kidney allografts many recipients develop a response against the graft during the second week; subsequently this subsides and the graft recovers. If the recipient is later challenged with kidney donor MHC antigens, it does not produce a normal secondary immune response. We suspect this is an example of loss of immunological memory and have questioned whether the presence of antigen is necessary to maintain the loss. We therefore transplanted spleens from these rats into syngeneic recipients, and then challenged with MHC antigen in a form which only provokes secondary responses. As controls, spleens were transplanted from previously immunized rats in which responses had subsided to background levels. The results showed rats receiving spleens from donors with enhanced kidneys produced little or no antibody after challenge. In contrast, control rats produced sustained secondary antibody responses. Approximately 2 months later, a similar re-challenge produced the same results. This experiment demonstrates that the loss of immunological memory by rats with enhanced kidney grafts does not require continued presence of antigen for its maintenance, and suggests that clonal inactivation or elimination is its basis rather than suppressor cells or auto-anti-idiotype antibody formation.

The Wembley Conference Centre Organisers have asked that participants should carry the programme of the meeting as a means of identification.

Further information about the Wembley Meeting may be obtained from Professor A.J.S.Davies or his secretary at the Chester Beatty Research Institute, Fulham Road, London SW3 6JB or telephone (01) 352-8133.

BRITISH SOCIETY FOR IMMUNOLOGY — BRITISH TRANSPLANTATION SOCIETY

JOINT MEETING

WEMBLEY CONFERENCE CENTRE

Thursday, 19th October, 1978

Avon Lecture Theatre — Chairman: Prof. P.J.Morris

10.00 a.m. Dr Hans WIGZELL (University of Uppsala, Sweden)
Generation and regulation of T cell specificity.

11.00 a.m. Coffee

11.30 a.m. Prof. J.Richard BATCHELOR (East Grinstead)
Present thoughts on the mechanisms of immunological enhancement.

12.30 p.m. Lunch

FACILITATION OF HOMOGRAFT ACCEPTANCE

Avon Two Lecture Theatre — Chairman: Prof. L. Brent

2.00 SHAND, F.L. (Beckenham) *
Selective elimination of alloreactive T cells by cyclophosphamide pretreatment in vitro.

2.15 WHITE, D.J.G., R.Y.Calne, K.Rolles and A.Plumb (Cambridge)
Mechanism of action of Cyclosporin A.

2.30 PIERPAOLI, W. and G.J.M.Maestroni (Zürich)
Successful engraftment of allogeneic bone marrow in mice.

2.45 MILTON, J.D. (Liverpool) *
Immunosuppressive activity of anti D end alloantibody.

3.00 GARVEY, J.F.W., P.R.Millard and P.J.Morris (Oxford) *
Failure of enhancing serum to prolong survival of foetal rat pancreas allografts.

3.15 GALLICO, G.G. and G.W.Butcher (Oxford and Cambridge)
Rat kidney transplantation: rejection and enhancement through sub-regions of the major histocompatibility complex.

3.30 Tea

Chairman: Dr J.A.Sachs

4.00 McKENZIE, J.L., J.W.Fabre and P.J.Morris (Oxford)
Studies on an in vitro assay to predict cross-reactivity of alloantisera for kidney graft enhancement in rats.

4.15 POOLE, M., J.R.Batchelor, A.Maynard and H.Burgos (East Grinstead)
Failure of immunological memory in rats with enhanced kidney allografts.

4.30 JEANNET, M., F.Harder and A.Montandon (Geneva) *
Blood transfusions, HLA and DR antibodies and kidney transplant survival: a prospective study.

4.45 EVANS, P.R., D.S.Smith, J.L.Smith, C.Spencer, M.Slapak and H.A.Lee (Southampton and Portsmouth) *
An analysis of serial pre and post transplant sera for antibody activity against neoplastic and normal B cells.

Abstracts for papers marked * appear on pages 11-13 of the full meeting programme.

ABSTRACTS (not for publication)

Mechanism of action of Cyclosporin A

D.J.G.WHITE, R.Y.Calne, K.Rolles and A.Plumb

Dept. of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge.

We have demonstrated Cyclosporin A (Sandoz Ltd) to be a potent suppressor of graft rejection in rats, rabbits, pigs, dogs, monkeys and man. It has been demonstrated in vitro that this agent inhibits T cell proliferation. We now report on the in vivo effect of this agent on T cell responsiveness.

Peripheral blood lymphocytes taken at weekly intervals from pigs with MHC mismatched orthotopic cardiac allografts being immunosuppressed with 25mg/kg/day of Cyclosporin A showed a marked specific depression in mixed lymphocyte reactions when stimulated with donor cells. These recipient lymphocytes gave normal or near normal responses when stimulated by third party cells. Pre-transplant cells and mixtures of pre and non-responsive post-transplant recipient cells gave normal or elevated responses when stimulated by donor cells, indicating that non-responsiveness in the post-transplant samples was not due to the presence of suppressor cells or donor specific cytotoxic cells. MHC mismatched porcine cardiac allografts receiving no treatment or receiving azathioprine and steroids have a median survival of only 6 days whereas of eight Cyclosporin A treated heart graft recipients six are still living at between 52 and 207 days (median 127).

Cyclosporin A has been tested in limited clinical trials in patients with cadaveric kidney transplants. We will present the results of our studies on the T cell function of these patients. The ability of Cyclosporin A to remove specifically that clone of lymphocytes from the blood which were reactive towards the graft will be discussed in relation to donor specific immunosuppression.

Successful engraftment of allogeneic bone marrow in mice

W.PIERPAOLI and G.J.M.Maestroni

Cell Biology Division, Institute of Anatomy, University of ZUrich, Switzerland.

The use of a combination of three drugs (5-hydroxytryptophan, haloperidol and phentolamine) has allowed to achieve a remarkable control of immunological reactions. The application of this system to allogeneic (homologous) bone marrow transplantation (BMT) in lethally irradiated mice (total body irradiation, TBI) seems now to constitute an efficient means for controlling the secondary disease (SD) ensuing in mice transplanted with foreign marrow after TBI, and for achieving a permanent chimerism. In addition, a new pre-conditioning regimen (preceeding TBI) has been developed which facilitates greatly the engraftment of foreign marrow. The final procedure we apply now is based on a) administration of the combination of drugs as a saline suspension sc in recipient mice; b) ip or iv inoculation of allogeneic bone marrow (over $20x10^6$ cells/mouse) one-two hours after the drugs; c) TBI, 800rad (Balb/c, C3H, C57BL/6) or 900rad (hybrid recipients) four-five hours after inoculation of bone marrow and finally d) a second inoculation of allogeneic bone marrow from the same donor strain, iv, immediately after TBI (over $20x10^6$ cells/mouse). This combination of drugs and allogeneic marrow in the pre-conditioning stage (before TBI) and a proper timing of inoculation of the different components allows the elimination of early or late mortality (high survival rate), avoidance of SD and induction of a permanent chimerism, as shown by different techniques. This method is now being applied to BMT in primates.

Rat kidney transplantation: rejection and enhancement through sub-regions of the major histocompatibility complex

G.Gregory GALLICO and Geoffrey W.Butcher

MRC Cellular Immunology Unit, Dunn School of Pathology, Oxford University and ARC Immunology Unit, Institute of Animal Physiology, Cambridge University.

The antigenic target for kidney rejection has not been established, and the antigenic target of enhancement is controversial. The genetics of the mouse major histocompatibility complex (MHC) are sufficiently well known to establish these points, but mice reject kidney allografts poorly. Rats reject kidneys well, but strains did not exist to enable precise genetic analysis.

A recombinant rat strain between the MHC of HO ($H\text{-}1^c$) and DA ($H\text{-}1^a$) was developed and bred to congenicity with the HO background. Analysis of this recombinant strain has led to the hypothesis that the rat MHC consists of an A sub-region analogous to the mouse K and D regions and a B sub-region analogous to the mouse Ir region. Also, a HO·B4 rat strain was developed with a DA ($H\text{-}1^a$) MHC congenic with a HO background.

In addition, we developed a microtiter radio-immunoassay for allospecific rat serum and through binding assays to B or T cells (separated by rosette depletion techniques or on the Fluorescence Activated Cell Sorter) or to RBC, we showed that the recombinant rat strain MHC, designated IR, encoded the K/D like antigens of $H\text{-}1^a$ and the Ia-like antigens of $H\text{-}1^c$.

Left orthotopic kidney transplants were performed between appropriate combinations of HO, IR, and HO·B4 rats. We conclude that whereas a kidney presenting a single haplotype MHC antigenic difference is readily rejected, kidneys presenting A or B sub-region differences alone are accepted. Skin grafts across each of the three antigenic differences were rejected. Renal rejection may require a combined A + B modified target antigen expression by the kidney as has been shown for cell mediated lympholysis. These results are analogous to the tissue typing correlation in human and Rhesus monkey kidney transplants where in unrelated host-donor combinations an LD match may be more important than SD.